Bin Zuo
Soochow University (Suzhou)
12 Papers
32 Citations
Bin Zuo is an academic researcher from Soochow University (Suzhou). The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Plasma microRNAs characterising patients with immune thrombocytopenic purpura
Bin Zuo,Juping Zhai,Lifang You,Yunxiao Zhao,Jianfeng Yang,Zhen Weng,Lan Dai,Qingyu Wu,Changgeng Ruan,Yang He +9 more
TL;DR: The results indicate that plasma miRNA profiles are altered in ITP patients and that the differentially expressed miRNAs may be used as biomarkers to improve the diagnosis of ITP.
30
18F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer.
Honglian Liu,Hao Sun,Bin Zhang,Shengli Liu,Shengming Deng,Zhen Weng,Bin Zuo,Jianfeng Yang,Yang He +8 more
TL;DR: It is suggested that ABZ induced the apoptosis of MDA-MB-231 cells by inhibiting glucose uptake, and it could be considered as a potential drug for TNBC cells.
17
Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients.
Juping Zhai,Mengyuan Ding,Tianjie Yang,Bin Zuo,Zhen Weng,Yunxiao Zhao,Jun He,Qingyu Wu,Changgeng Ruan,Yang He +9 more
TL;DR: Elevated levels of autoantibodies against platelet glycoproteins GPIX, GPIb, GPIIIa, GPIIb and P-selectin were detected by the quantitative FCIA in ITP patients compared to non-ITP patients or healthy controls, and reduced levels of platelet autoantibia could be confirmed by the authors' quantitativeFCIA inITP patients after corticosteroid treatment.
A novel monoclonal antibody targeting a novel epitope of VE‑cadherin inhibits vasculogenic mimicry of lung cancer cells
TL;DR: It is suggested that the EC4 domain participates in VE‑cadherin clustering and the antibody targeting the EC1 and EC3 domain of VE-cadhersin may be a promising anti-vasculogenic mimicry agent for cancer treatment.
An improved flow cytometric immunobead array to detect autoantibodies in plasma from patients with immune thrombocytopenic purpura.
TL;DR: This new FCIA eliminated the need of isolating platelets from ITP patients without compromising assay sensitivity and accuracy in predicting ITP, and may be more suitable for ITP diagnosis in clinical laboratory settings.
11